TD Waterhouse Canada Inc. Takes $2.03 Million Position in Carlsmed, Inc. $CARL

TD Waterhouse Canada Inc. bought a new stake in Carlsmed, Inc. (NASDAQ:CARL) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 152,242 shares of the company’s stock, valued at approximately $2,026,000. TD Waterhouse Canada Inc. owned about 0.57% of Carlsmed at the end of the most recent reporting period.

Separately, Kornitzer Capital Management Inc. KS acquired a new position in shares of Carlsmed in the third quarter valued at approximately $736,000.

Carlsmed Stock Down 2.0%

Shares of NASDAQ:CARL opened at $12.42 on Friday. The company has a market cap of $330.25 million and a P/E ratio of -3.72. The firm’s 50-day simple moving average is $13.41. The company has a current ratio of 12.03, a quick ratio of 11.91 and a debt-to-equity ratio of 0.14. Carlsmed, Inc. has a fifty-two week low of $11.45 and a fifty-two week high of $17.19.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.05.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Wall Street Zen cut shares of Carlsmed from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Truist Financial reissued a “buy” rating and issued a $20.00 target price (up previously from $18.00) on shares of Carlsmed in a research note on Friday, November 7th. Weiss Ratings reiterated a “sell (e-)” rating on shares of Carlsmed in a research note on Monday, December 22nd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Carlsmed in a research report on Friday, January 9th. Finally, BTIG Research restated a “buy” rating and issued a $24.00 price objective on shares of Carlsmed in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Carlsmed presently has an average rating of “Moderate Buy” and a consensus target price of $21.33.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).